si:ch211-194e15.5 Antibody

What is si:ch211-194e15.5 and how has its nomenclature evolved?

Si:ch211-194e15.5 is the previous designation for what is now officially named nhsl3 (NHS like 3) in zebrafish, a protein-coding gene located on chromosome 19. The gene encodes a protein predicted to be involved in cell differentiation processes in zebrafish development and function. According to zebrafish gene databases, this nomenclature change reflects improved understanding of the gene's function and its homology relationships with genes in other species. The protein is orthologous to the human NHSL3 (NHS like 3) gene, suggesting evolutionary conservation of function across vertebrate species . Understanding the nomenclature history is essential for researchers when searching literature and databases, as older publications may exclusively reference the gene by its previous si:ch211-194e15.5 designation.

What is the functional significance of nhsl3 (si:ch211-194e15.5) in zebrafish models?

The nhsl3 gene in zebrafish encodes a protein that belongs to the actin remodeling regulator NHS-like protein family, suggesting its involvement in cytoskeletal organization and dynamics. Based on genomic analysis, the protein is predicted to participate in cell differentiation processes, which are crucial for proper development and tissue formation in zebrafish. The protein contains specific domains characteristic of the NHS-like family (IPR024845), which further supports its role in actin cytoskeleton regulation . While direct experimental phenotype data is currently limited, the orthology relationship with human NHSL3 provides insight into potential functions related to cellular structure and developmental pathways. Understanding these functions is paramount for researchers seeking to use nhsl3 antibodies in developmental biology studies or when using zebrafish as a model for human diseases related to cytoskeletal regulation.

What criteria should be considered when selecting an antibody against nhsl3 for research applications?

When selecting an antibody against nhsl3 (formerly si:ch211-194e15.5), researchers should prioritize several critical factors to ensure experimental success. First, evaluate antibody specificity through documented validation techniques such as Western blotting against zebrafish tissue lysates, where the antibody should detect bands at the expected molecular weight of the nhsl3 protein isoforms (which may range from approximately 1325-1400 amino acids based on known protein variants) . Second, consider the antibody's application compatibility, as certain antibodies may perform well in techniques like immunohistochemistry but poorly in others such as immunoprecipitation or flow cytometry. Third, researchers should assess whether antibodies target specific domains of the nhsl3 protein, such as the actin remodeling regulator NHS-like domain, which may be important depending on research objectives. Finally, examine epitope location carefully, as antibodies targeting different regions (N-terminal, C-terminal, or internal domains) may yield different results based on protein conformation and accessibility in experimental conditions.

How should experiments be designed to validate the specificity of an nhsl3 antibody in zebrafish?

Designing robust validation experiments for nhsl3 antibodies requires a multi-technique approach to confirm specificity before proceeding with primary research. Begin with Western blot analysis using zebrafish tissue lysates from different developmental stages, comparing wild-type samples with negative controls where applicable, to verify that the antibody detects proteins of the expected molecular weight for nhsl3 isoforms (approximately 1325-1400 amino acids based on UniProt entries) . Implement immunohistochemistry or immunofluorescence on zebrafish tissue sections to confirm proper localization patterns consistent with predicted cellular functions of nhsl3 in cell differentiation. Consider using a combination of antibodies targeting different epitopes of the nhsl3 protein (similar to approaches used for other zebrafish proteins where antibodies target N-terminal, C-terminal, and mid-region epitopes) to strengthen validation through consistent detection patterns . For definitive validation, perform knockdown or knockout experiments using morpholinos or CRISPR-Cas9 to demonstrate reduced or absent antibody signal in specimens with diminished nhsl3 expression, which provides compelling evidence of antibody specificity when compared to wild-type controls.

What are the optimal experimental controls when using nhsl3 antibodies in zebrafish research?

Implementing comprehensive controls is essential when working with nhsl3 antibodies to ensure reliable and interpretable results. Primary negative controls should include tissue samples from nhsl3 knockdown or knockout zebrafish models, which should exhibit significantly reduced or absent antibody signal compared to wild-type specimens. Include isotype controls matching the nhsl3 antibody's host species and immunoglobulin class to identify any non-specific binding that may occur through Fc receptor interactions or other non-target mechanisms. For peptide competition assays, pre-incubate the antibody with excess purified nhsl3 peptide (corresponding to the epitope region) before application to samples, which should result in signal elimination if the antibody is specifically binding to nhsl3. Consider cross-reactivity controls using tissues expressing proteins with similar domains to nhsl3, particularly other NHS-like family members, to ensure the antibody doesn't detect related proteins. Finally, implement positive controls using tissues known to express nhsl3 at high levels, based on transcriptomic data or previous expression studies, to confirm that the antibody can detect the protein under optimal conditions.

How can researchers integrate nhsl3 antibody-based studies with other molecular techniques for comprehensive analysis?

Creating an integrated research approach that combines nhsl3 antibody techniques with complementary molecular methods strengthens data validity and provides deeper mechanistic insights. Pair immunohistochemistry or immunofluorescence using nhsl3 antibodies with in situ hybridization for nhsl3 mRNA to correlate protein localization with gene expression patterns during zebrafish development. Complement antibody-based protein detection with quantitative RT-PCR to monitor transcriptional changes in nhsl3 expression under experimental conditions, providing a dual perspective on gene regulation at both RNA and protein levels. Consider implementing proximity ligation assays using nhsl3 antibodies alongside antibodies against predicted interaction partners to visualize and quantify protein-protein interactions in situ, particularly with proteins involved in actin cytoskeleton regulation given nhsl3's predicted function . Integrate ChIP-seq approaches using nhsl3 antibodies (if suitable for immunoprecipitation) to identify genomic binding sites if nhsl3 has potential transcriptional regulatory functions, similar to approaches used for other developmental regulators. Finally, combine traditional antibody-based detection with newer technologies like antibody-based proximity labeling (BioID or APEX) to identify the nhsl3 protein interactome in specific developmental contexts.

What dilution ranges and incubation conditions should be tested when establishing protocols for nhsl3 Western blotting?

Establishing optimal Western blotting protocols for nhsl3 antibodies requires systematic testing of multiple parameters to achieve specific detection with minimal background. Begin with a broad antibody dilution series (1:250 to 1:2000) to determine the optimal concentration that maximizes specific signal while minimizing background, noting that monoclonal antibody combinations against related zebrafish proteins have shown effective detection at dilutions corresponding to ELISA titers of 10,000 (approximately 1 ng detection sensitivity) . Test both standard overnight incubations at 4°C and shorter incubations (3-4 hours) at room temperature, as some epitopes may be more accessible under different temperature conditions, particularly for antibodies targeting different regions of the protein (N-terminus, C-terminus, or internal domains). Optimize blocking conditions using 5% non-fat dry milk in TBS-T as a starting point, with alternative blocking agents like bovine serum albumin (3-5%) tested if milk proteins cause interference or high background. For membrane transfer of high molecular weight proteins like nhsl3 (1325-1400 amino acids) , consider extended transfer times or specialized transfer conditions for large proteins, such as overnight transfer at lower voltage or using transfer buffers with reduced methanol content. Finally, evaluate different detection systems including chemiluminescence, fluorescence, and colorimetric methods to determine which provides the optimal signal-to-noise ratio for specific research needs.

What approaches should be used to quantify nhsl3 expression levels using antibody-based methods?

Accurate quantification of nhsl3 expression requires rigorous technical approaches and appropriate controls to ensure reliable data interpretation. For Western blot quantification, implement normalization against multiple housekeeping proteins (such as beta-actin, GAPDH, and alpha-tubulin) rather than a single reference protein to account for potential experimental variability across different developmental stages or tissue types. When performing immunohistochemistry quantification, utilize automated image analysis software with standardized parameters for signal intensity measurement, employing thresholding techniques optimized specifically for nhsl3 staining patterns and counterstained with DAPI for nuclear identification. For flow cytometry applications, develop compensation matrices using single-color controls to account for spectral overlap when nhsl3 is detected alongside other proteins in multiplex analyses, with fluorescence-minus-one (FMO) controls to establish accurate gating strategies. Consider implementing ELISA-based quantification using purified recombinant nhsl3 protein standards at known concentrations to generate standard curves for absolute quantification, similar to approaches used for other zebrafish proteins . For all quantification methods, perform technical replicates (minimum of three) and biological replicates (different specimens) to assess method reproducibility and account for biological variation, with statistical analysis appropriate to the experimental design.

What are common causes of non-specific binding when using nhsl3 antibodies and how can they be minimized?

Non-specific binding is a frequent challenge when working with antibodies against zebrafish proteins like nhsl3, but several targeted approaches can minimize these issues. Cross-reactivity with related NHS-like family proteins is a primary concern given the conserved domains shared among these proteins; this can be addressed by using epitope-specific antibodies targeting unique regions of nhsl3 rather than conserved domains, and validating specificity through Western blotting against recombinant proteins from each family member. High background in immunohistochemistry often stems from inadequate blocking; improve this by extending blocking time (2-3 hours at room temperature), increasing blocking agent concentration (up to 10% normal serum or 5% BSA), and adding 0.1-0.3% Triton X-100 to enhance penetration and reduce non-specific membrane binding. Zebrafish tissues may contain endogenous biotin or peroxidase activity that interferes with detection systems; mitigate this by incorporating avidin/biotin blocking steps before antibody application or using peroxidase quenching with 3% hydrogen peroxide for 10-15 minutes prior to primary antibody incubation. Antibody concentration is often critical, as too high concentrations increase non-specific binding while too low concentrations may yield insufficient signal; perform careful titration experiments comparing signal-to-noise ratios across a range of concentrations to identify the optimal working dilution for each application . Finally, consider the influence of fixation duration and processing parameters, as overfixation can increase background through non-specific protein crosslinking while underfixation may compromise tissue preservation.

How can researchers troubleshoot weak or absent signal when using nhsl3 antibodies?

When confronting weak or absent signal in nhsl3 antibody applications, a systematic troubleshooting approach can identify and resolve underlying issues. Begin by confirming nhsl3 expression in the specific tissue and developmental stage being examined, as the lack of existing expression data in databases suggests potential spatial or temporal specificity of expression that might not align with experimental conditions . For antigen retrieval challenges, test multiple methods sequentially, including heat-induced epitope retrieval with different buffers (citrate pH 6.0, Tris-EDTA pH 9.0), enzymatic retrieval with proteinase K or trypsin, and extended retrieval times, as NHS-like family proteins may have complex conformational epitopes requiring specific unmasking conditions. Consider epitope accessibility issues, particularly for antibodies targeting internal domains, by testing antibodies directed against different regions of the protein (N-terminal, C-terminal, and internal epitopes) similar to the approach used for other zebrafish proteins . For Western blotting applications, implement specialized extraction methods using stronger detergents (RIPA buffer supplemented with 0.5-1% SDS) and mechanical disruption to ensure complete protein solubilization, as cytoskeletal-associated proteins like nhsl3 may resist standard extraction protocols. Finally, evaluate antibody quality and storage conditions, as antibody degradation through improper handling, repeated freeze-thaw cycles, or extended storage at diluted concentrations can significantly diminish antibody performance; consider utilizing fresh aliquots of antibody and validating with positive control samples where nhsl3 expression is highest.

What quality control measures should be implemented when producing or validating new batches of nhsl3 antibodies?

Implementing rigorous quality control procedures for nhsl3 antibodies ensures consistency and reliability across experiments. For new antibody production, validate epitope selection by confirming that target sequences have minimal homology with other zebrafish proteins using BLAST analysis, particularly checking for similarity with other NHS-like family members to minimize cross-reactivity concerns. Perform comprehensive batch-to-batch validation through side-by-side testing of new and reference antibody lots using identical samples and protocols, quantifying signal intensity and background levels to ensure consistent performance characteristics across multiple detection methods. Implement ELISA-based testing to determine antibody titer and antigen-binding capacity of each batch, establishing minimum acceptable thresholds similar to the 10,000 ELISA titer benchmark used for other zebrafish protein antibodies . For polyclonal antibodies, consider affinity purification against the specific immunogen to enrich for antibodies targeting the desired epitope, reducing batch variability and improving specificity. Maintain detailed documentation of validation experiments for each antibody batch, including Western blot images showing expected band patterns, immunohistochemistry results demonstrating proper localization, and quantitative metrics of performance such as signal-to-noise ratios and detection limits. Finally, establish long-term storage validation by testing antibody performance after defined storage periods (3, 6, and 12 months) under recommended conditions to determine shelf-life and detect any time-dependent deterioration in antibody quality.

How can machine learning approaches enhance antibody-antigen binding prediction for custom nhsl3 antibody development?

Machine learning offers powerful capabilities for optimizing nhsl3 antibody development through improved antibody-antigen binding prediction. Researchers can implement library-on-library approaches to screen multiple antibody candidates against various nhsl3 epitopes simultaneously, generating comprehensive binding data that captures many-to-many relationships between potential antibodies and antigens . These data can train machine learning models to predict binding affinities, helping researchers identify the most promising antibody candidates without exhaustive experimental testing. For out-of-distribution challenges when dealing with novel nhsl3 epitopes not represented in training data, active learning strategies provide significant advantages by iteratively expanding labeled datasets based on model uncertainty, potentially reducing the number of required antigen variants by up to 35% compared to random sampling approaches . Researchers should incorporate structural information about the NHS-like domain (IPR024845) into these models to enhance prediction accuracy through attention to domain-specific binding characteristics . When selecting machine learning architectures, consider ensemble methods that combine multiple prediction approaches, as these have demonstrated superior performance in antibody-antigen binding prediction tasks across diverse protein families.

What strategies can be employed for multiplex imaging of nhsl3 in relation to other cytoskeletal regulators in zebrafish development?

Advanced multiplex imaging of nhsl3 alongside other cytoskeletal regulators requires sophisticated technical approaches to visualize complex protein relationships during zebrafish development. Implement spectral unmixing microscopy using combinations of fluorophores with distinct excitation and emission profiles, allowing simultaneous visualization of nhsl3 and 3-4 additional proteins involved in actin remodeling or related cytoskeletal processes. Consider cyclic immunofluorescence methods where sequential rounds of antibody staining, imaging, and signal quenching enable visualization of 10+ proteins on the same tissue section, providing comprehensive spatial relationship data between nhsl3 and its potential interaction partners. Proximity ligation assays offer particular value for detecting protein-protein interactions between nhsl3 and other cytoskeletal regulators with sub-cellular resolution, generating fluorescent signals only when proteins are within 40nm of each other. For deeper tissue imaging in intact zebrafish embryos, implement light-sheet microscopy combined with tissue clearing techniques (such as CLARITY or iDISCO), enabling whole-embryo visualization of nhsl3 distribution in relation to the developing cytoskeleton with minimal photobleaching. Complement protein-level imaging with simultaneous visualization of nhsl3 transcripts using multiplexed fluorescent in situ hybridization techniques like RNAscope or MERFISH, correlating protein localization with active sites of gene expression during developmental processes.

How can nhsl3 antibodies be utilized in zebrafish disease models related to cytoskeletal dysfunction?

Leveraging nhsl3 antibodies in zebrafish disease models provides valuable insights into cytoskeletal pathologies with human disease relevance. Researchers should establish baseline nhsl3 expression patterns throughout normal zebrafish development using antibody-based imaging, creating a comprehensive atlas of expression across tissues and developmental timepoints for comparison with disease models. In genetic models of human cytoskeletal disorders, particularly those affecting actin remodeling pathways, nhsl3 antibodies can be used to monitor potential compensatory changes in nhsl3 expression or localization, revealing dynamic responses to primary cytoskeletal defects. Consider using nhsl3 antibodies in conjunction with live-cell imaging techniques in transgenic zebrafish lines, where specific cell populations are fluorescently labeled to track nhsl3-expressing cells during disease progression or treatment response. For drug discovery applications, high-content screening approaches incorporating nhsl3 antibody staining can evaluate compounds that potentially normalize aberrant cytoskeletal organization, using quantitative image analysis to measure changes in nhsl3 distribution or expression levels. Finally, explore cross-species applications by testing whether antibodies developed against zebrafish nhsl3 recognize orthologous proteins in human samples, particularly in tissues derived from patients with cytoskeletal disorders, which could establish direct translational relevance of findings from zebrafish models to human disease mechanisms.

What emerging technologies might advance nhsl3 antibody applications in zebrafish research?

Several emerging technologies hold promise for revolutionizing nhsl3 antibody applications in zebrafish research over the coming years. Advances in single-cell proteomics methods, including mass cytometry (CyTOF) adapted for zebrafish tissues, could enable high-dimensional analysis of nhsl3 expression alongside dozens of other proteins at single-cell resolution, revealing heterogeneity within cell populations that express this cytoskeletal regulator. CRISPR-based protein tagging approaches offer opportunities to insert epitope tags directly into the endogenous nhsl3 gene, creating knockin zebrafish lines where validated commercial antibodies against common tags (HA, FLAG, V5) can be used for consistent detection without relying on custom nhsl3 antibodies. Super-resolution microscopy techniques like STORM, PALM, and STED continue to improve, potentially enabling visualization of nhsl3 protein organization at nanometer scales, revealing its precise structural relationships within the cytoskeletal network beyond conventional microscopy limitations. Active learning approaches for antibody development, as described in recent research, could accelerate the creation of more specific and sensitive nhsl3 antibodies by reducing experimental iterations needed to identify optimal antibody candidates by up to 35% . Finally, integrating spatial transcriptomics with antibody-based protein detection through techniques like Spatial-seq or 10X Visium, combined with nhsl3 immunostaining, would create multi-omic maps correlating protein localization with gene expression patterns across intact zebrafish tissues, providing unprecedented insights into nhsl3 regulation and function.